Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:603811'
s EV-to-FCF Range Over the Past 10 Years
Min: -6013.18 Med: 15.61 Max: 475.26
Current: 14.13
During the past 13 years, the highest EV-to-FCF of Zhejiang Cheng Yi Pharmaceutical Co was 475.26. The lowest was -6013.18. And the median was 15.61.
SHSE:603811's EV-to-FCF is ranked better than 65.55% of 569
companies
in the Drug Manufacturers industry
Industry Median: 21.6
vs SHSE:603811: 14.13
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhejiang Cheng Yi Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Zhejiang Cheng Yi Pharmaceutical Co's share price for today is ¥7.43.
Zhejiang Cheng Yi Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.435.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Zhejiang Cheng Yi Pharmaceutical Co EV-to-FCF Related Terms
Zhejiang Cheng Yi Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Cheng Yi Pharmaceutical Co EV-to-FCF Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Cheng Yi Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Cheng Yi Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Cheng Yi Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Zhejiang Cheng Yi Pharmaceutical Co's EV-to-FCF falls into.
Zhejiang Cheng Yi Pharmaceutical Co's current Enterprise Value is ¥3,097.7 Mil.
Zhejiang Cheng Yi Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥219.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) has a EV-to-FCF of 14.13 as of Aug. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhejiang Cheng Yi Pharmaceutical Co and its competitors. This is near median its historical median of 15.61. According to the industry distribution chart, Zhejiang Cheng Yi Pharmaceutical Co ranks #196 out of 569 companies in the Drug Manufacturers industry, placing it in the top 34.4%.
Is Zhejiang Cheng Yi Pharmaceutical Co's EV-to-FCF too high?
Zhejiang Cheng Yi Pharmaceutical Co's current EV-to-FCF of 14.13 is near median its 10-year median of 15.61. The Drug Manufacturers industry median EV-to-FCF is 21.60. Zhejiang Cheng Yi Pharmaceutical Co's value of 14.13 is 34.6% below this industry median. Based on the distribution chart, Zhejiang Cheng Yi Pharmaceutical Co ranks #196 out of 569 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zhejiang Cheng Yi Pharmaceutical Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Cheng Yi Pharmaceutical Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Cheng Yi Pharmaceutical Co ranks #196 out of 569 companies for EV-to-FCF. This puts Zhejiang Cheng Yi Pharmaceutical Co in the upper half of its industry. The industry median EV-to-FCF is 21.60. Zhejiang Cheng Yi Pharmaceutical Co's value of 14.13 is 34.6% below this benchmark. While the company's 10-year median is 15.61 vs. the industry median of 21.60, Zhejiang Cheng Yi Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.60, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Cheng Yi Pharmaceutical Co's current EV-to-FCF of 14.13 is 34.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhejiang Cheng Yi Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Cheng Yi Pharmaceutical Co's current EV-to-FCF is 14.13, which is near median its own 10-year median of 15.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Cheng Yi Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥8.45, compared to a current price of ¥7.43 — trading 12.1% below its estimated fair value. The current EV-to-FCF is 14.13, which is near median its 10-year median of 15.61 and 34.6% below the Drug Manufacturers industry median of 21.60. Zhejiang Cheng Yi Pharmaceutical Co's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811), the current EV-to-FCF is 14.13 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Cheng Yi Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥7.43 is trading 12.1% below its estimated GF Value™ of ¥8.45.
GuruFocus considers Zhejiang Cheng Yi Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603811:
EV-to-FCF: 14.13 (near median its 10-year median of 15.61)
GF Value™: ¥8.45 vs. price of ¥7.43 (12.1% below fair value)
Industry Position: 34.6% below the Drug Manufacturers median (#196 of 569)
No single metric tells the full story. See the SHSE:603811 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Cheng Yi Pharmaceutical Co Ltd is a pharmaceutical company that produces capsules, injections, tablets, APIs, and pharmaceutical intermediates in China. Its main products include glucosamine hydrochloride raw materials and preparations, torasemide injection and capsules, Gastrodin raw materials, ribavirin and purine raw materials, and so on.
85GF Score
Get the complete analysis for SHSE:603811
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603811 has been successfully added to your 
